药物发现和开发的基本原则

关键字：类型：

下载页码(大于0,小于537)：

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

药物发现和开发的基本原则 1336条(本栏目收费,不能显示细节,电话13136136841)

Cytochalasin B, 357–358, 357f 357 358 357

Cytochrome P450 3A4 (CYP3A4), 348–349,360–362 348 349 360 362

Cytotoxicity, 354–356, 355f 354 356 355

acute, 353–354, 369 353 354 369

chronic, 353–354, 376 353 354 376

Dalcetrapib (JTT-705), 12–13, 12f1,4-Diazepames CB2 agonists, 282–283 12 13 121 282 283

tomography (SPECT), 427–428,427t 427 428 427

sleep/wake cycle, 435 435

ultrasound, 432 432

X-ray computed tomography (X-ray CT), 425 425

mechanism biomarkers, 419 419

outcome biomarkers, 419–420 419 420

pharmacogenomic biomarkers, 420 420

vs. surrogate end points, 423–424 423 424

target engagement biomarkers, 419 419

toxicity biomarkers, 420 420

Biopharmaceutics Classification System (BCS), 262, 262f 262 262

Biotechnology, 59 59

Biotin, 153–154, 153f 153 154 153

Bupropion, 521–522, 521f 521 522 521

California Institute for Biomedical

Research (Calibr), 463–464 463 464

cAMP signaling. See Cyclic adenosine

monophosphate (cAMP) signaling

Cardiovascular disease animal model. See

Animal models, disease states,

cardiovascular disease animal

model

Cardiovascular safety and toxicology

acute cardiovascular safety, 369 369

最新招商产品更多>>

浙ICP备16010490号-2 增值电信业务经营许可证：浙B2-20220931　互联网药品信息服务资格证书编号：(浙)-经营性2023-0215　

浙公网安备:330683240604819103159
　医药代理商群１：

医药代理商群２：

医药代理商群３：